Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

PharmaCyte Biotech, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LAS VEGAS--(BUSINESS WIRE)--PHARMACYTE BIOTECH, INC. (NASDAQ:PMCB) (PHARMACYTE OR THE COMPANY), TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED $7 MILLION FINANCING. AS OF APRIL 30, 2025, PHARMACYTE HAD APPROXIMATELY $15.5 MILLION IN CASH AND ALSO HOLDS OVER $30 MILLION OF SECURITIES AS REFLECTED IN THE COMPANY'S MOST RECENT 10K. WITH THE ADDITION OF THE $7 MILLION IN PROCEEDS FROM THIS FINANCING, THE COMPANY'S BALANCE SHEET HAS BEEN FURTHER STRENGTHENED, PROVIDING SIGNIFICANT FINAN.

PHARMACYTE BIOTECH, INC. ANNOUNCES CLOSING OF $7 MILLION FINANCING

LAS VEGAS--(BUSINESS WIRE)--PHARMACYTE BIOTECH, INC. (NASDAQ:PMCB) (PHARMACYTE OR THE COMPANY) ANNOUNCED TODAY THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT FOR A $7.0 MILLION FINANCING WITH EXISTING INVESTORS INVOLVING THE SALE OF 7,000 SHARES OF ITS NEWLY DESIGNATED SERIES C CONVERTIBLE PREFERRED STOCK ("PREFERRED STOCK"), WITH A STATED VALUE OF $1,000 PER SHARE, CONVERTIBLE INTO AN AGGREGATE OF 7,000,000 SHARES OF ITS COMMON STOCK AND UNREGISTERED COMMON STOCK PURCHASE WARRANT.

PHARMACYTE BIOTECH, INC. ANNOUNCES $7 MILLION CAPITAL RAISE LED BY EXISTING INVESTORS

BALTIMORE--(BUSINESS WIRE)---- $MYMD--MYMD PHARMACEUTICALS, INC. (NASDAQ: MYMD) (MYMD OR THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY COMMITTED TO DEVELOPING NOVEL THERAPIES FOR AGE-RELATED DISEASES, AND AUTOIMMUNE AND INFLAMMATORY CONDITIONS, TODAY ANNOUNCED THAT IT HAS SECURED $7 MILLION IN COMMITMENTS IN TWO PRIVATE PLACEMENT FUNDING ROUNDS LED BY A STRATEGIC INVESTOR, PHARMACYTE BIOTECH, INC. (NASDAQ: PMCB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR CAN.

MYMD PHARMACEUTICALS SECURES STRATEGIC INVESTMENTS

LAS VEGAS--(BUSINESS WIRE)--PHARMACYTE BIOTECH, INC. (NASDAQ: PMCB) (PHARMACYTE OR THE COMPANY), TODAY ANNOUNCED A $7 MILLION INVESTMENT IN MYMD PHARMACEUTICALS, INC. (NASDAQ:MYMD) (MYMD) A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY COMMITTED TO DEVELOPING NOVEL THERAPIES FOR AGE-RELATED DISEASES, AUTOIMMUNE AND INFLAMMATORY CONDITIONS. MYMD HAS ANNOUNCED POSITIVE DATA FOR A 40-PATIENT PHASE 2 CLINICAL TRIAL FOR ITS LEAD PRODUCT, MYMD-1 IN SARCOPENIA, AND IS MOVING ITS CLINICAL PROGRAM FORW.

PHARMACYTE BIOTECH MAKES $7 MILLION STRATEGIC INVESTMENT IN MYMD, A BIOPHARMACEUTICAL COMPANY FOCUSED ON INFLAMMATORY DISEASE

LAS VEGAS--(BUSINESS WIRE)--PHARMACYTE BIOTECH, INC. (NASDAQ: PMCB) (PHARMACYTE OR THE COMPANY) ANNOUNCES IT HAS MADE A $5 MILLION INVESTMENT IN FEMASYS, INC. (NASDAQ:FEMY) (FEMASYS), A BIOMEDICAL COMPANY FOCUSED ON MEETING SIGNIFICANT UNMET NEEDS FOR WOMEN WORLDWIDE. FEMASYS OFFERS A BROAD PORTFOLIO OF IN-OFFICE, ACCESSIBLE SOLUTIONS, INCLUDING A LEAD LATE-STAGE PRODUCT CANDIDATE AND INNOVATIVE THERAPEUTIC AND DIAGNOSTIC PRODUCTS. THIS IS THE COMPANY'S FIRST INVESTMENT IN EXTERNALLY DEVE.

PHARMACYTE BIOTECH ACQUIRES $5 MILLION STAKE IN EMERGING WOMEN'S HEALTH INNOVATOR FEMASYS, INC.

LAS VEGAS--(BUSINESS WIRE)--PHARMACYTE BIOTECH, INC. (NASDAQ: PMCB) (PHARMACYTE OR THE COMPANY) PROVIDES AN UPDATE ON ITS INVESTIGATION OF ITS CELL-IN-A-BOX TECHNOLOGY AND INITIAL NEXT STEPS IN DEVELOPMENT. FOLLOWING A COMPREHENSIVE SCIENTIFIC REVIEW OF AMASSED DATA, THE COMPANY IS IN THE PROCESS OF REQUESTING A MEETING WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR GUIDANCE ON FURTHER DEVELOPMENT OF THE TECHNOLOGY. THE MEETING IS EXPECTED TO OCCUR DURING THE FIRST QUARTER OF 2024. IN.

PHARMACYTE BIOTECH PROVIDES CORPORATE UPDATE ON CELL-IN-A-BOX TECHNOLOGY

LAS VEGAS--(BUSINESS WIRE)--PHARMACYTE BIOTECH, INC. (NASDAQ: PMCB) (PHARMACYTE OR THE COMPANY) TODAY ANNOUNCES THE FINAL RESULTS OF ITS PREVIOUSLY ANNOUNCED TENDER OFFER TO ACQUIRE UP TO 7,750,000 MILLION SHARES OF THE COMPANY'S COMMON STOCK, PAR VALUE $0.001 PER SHARE, AT A PRICE OF $3.25 PER SHARE IN CASH, LESS ANY APPLICABLE WITHHOLDING TAXES AND WITHOUT INTEREST. THE TENDER OFFER EXPIRED ONE MINUTE AFTER 11:59 P.M. ON JUNE 9, 2023, AND WAS FUNDED ENTIRELY THROUGH THE COMPANY'S CASH ON.

PHARMACYTE BIOTECH ANNOUNCES FINAL RESULTS OF TENDER OFFER

LAS VEGAS--(BUSINESS WIRE)--PHARMACYTE BIOTECH, INC. (NASDAQ: PMCB) (PHARMACYTE OR THE COMPANY) TODAY ANNOUNCES A CASH TENDER OFFER FOR UP TO 7,750,000 SHARES AT $3.25 PER SHARE, LESS ANY APPLICABLE WITHHOLDING TAXES AND WITHOUT INTEREST. THE COMPANY ALSO ANNOUNCES THAT IT HAS COMPLETED A PRIVATE PLACEMENT FINANCING OF CONVERTIBLE REDEEMABLE PREFERRED STOCK AND WARRANTS FROM EXISTING INVESTORS, RAISING GROSS PROCEEDS OF APPROXIMATELY $35 MILLION IN A PRIVATE PLACEMENT FINANCING OF CONVERTIBLE REDEEMABLE PREFERRED STOCK AND WARRANTS FROM EXISTING INVESTORS. TENDER OFFER THE COMPANY INTENDS TO COMMENCE THE TENDER OFFER TODAY, MAY 11, 2023. THE TENDER OFFER IS SCHEDULED TO EXPIRE AT 11:59 P.M., NEW YORK CITY TIME, ON JUNE 9, 2023, UNLESS EXTENDED OR EARLIER TERMINATED (THE EXPIRATION DATE). THE PURCHASE OF COMMON STOCK IN CONNECTION WITH THE TENDER OFFER WILL BE FUNDED ENTIRELY THROUGH THE COMPANYS CASH ON HAND. STOCKHOLDERS MUST VALIDLY TENDER AND NOT VALIDLY WITHDRAW THEIR COMMON STOCK BEFORE THE EXPIRATION DATE TO BE ELIGIBLE TO PARTICIPATE IN THE TENDER OFFER. TENDERED SHARES OF COMMON STOCK MAY ONLY BE WITHDRAWN ON OR BEFORE THE EXPIRATION DATE. THE TENDER OFFER WILL BE SUBJECT TO VARIOUS TERMS AND CONDITIONS AS WILL BE DESCRIBED IN THE OFFER TO PURCHASE. THE DEPOSITARY FOR THE TENDER OFFER WILL BE AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC, AND THE INFORMATION AGENT FOR THE TENDER OFFER WILL BE D.F. KING & CO., INC. NONE OF THE COMPANY OR ITS BOARD OF DIRECTORS, THE INFORMATION AGENT FOR THE TENDER OFFER, OR THE DEPOSITARY FOR THE TENDER OFFER WILL MAKE ANY RECOMMENDATION TO SHAREHOLDERS AS TO WHETHER TO TENDER OR REFRAIN FROM TENDERING THEIR SHARES IN THE TENDER OFFER. SHAREHOLDERS MUST MAKE THEIR OWN DECISION AS TO HOW MANY SHARES THEY WILL TENDER, IF ANY. SHAREHOLDERS SHOULD CONSULT THEIR FINANCIAL AND TAX ADVISORS IN MAKING THIS DECISION. PHARMACYTES CEO JOSH SILVERMAN COMMENTED, WE CONTINUE TO EVALUATE OUR CURRENT ASSETS, WHICH ARE INTENDED TO ADDRESS A HI

PHARMACYTE BIOTECH ANNOUNCES CASH TENDER OFFER FOR UP TO 7,750,000 SHARES AT $3.25 PER SHARE

LAS VEGAS--( BUSINESS WIRE )--PHARMACYTE BIOTECH, INC. (NASDAQ:PMCB) (PHARMACYTE OR THE COMPANY), A BIOTECHNOLOGY COMPANY FOCUSED ON EVALUATING ITS SIGNATURE LIVE-CELL ENCAPSULATION TECHNOLOGY, CELL-IN-A-BOX  FOR POTENTIAL DEVELOPMENT OF CELLULAR THERAPIES FOR CANCER, DIABETES AND MALIGNANT ASCITES, ANNOUNCED TODAY THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED A SECOND SHARE REPURCHASE PROGRAM TO REPURCHASE UP TO $10 MILLION OF PHARMACYTE'S OUTSTANDING COMMON STOCK. THIS SECOND SHARE REPURCHASE AUTHORIZATION IS EFFECTIVE IMMEDIATELY FOR A TWO-YEAR PERIOD. PHARMACYTE EXPECTS TO FUND THE PROGRAM WITH ITS AVAILABLE CASH. THE COMPANY ENACTED A SIMILAR PROGRAM IN JUNE 2022.

PHARMACYTE BIOTECH TO IMPLEMENT SECOND $10-MILLION SHARE REPURCHASE PLAN

TOPICS TO INCLUDE CONTINUED ANALYSIS OF FDA'S CLINICAL HOLDON IND FOR CELL-IN-A-BOX TOPICS TO INCLUDE CONTINUED ANALYSIS OF FDA'S CLINICAL HOLDON IND FOR CELL-IN-A-BOX

PharmaCyte Biotech, Inc.

PMCB

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PharmaCyte Biotech, Inc.

PMCB.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PMCB